Andy Lee, MD
Clinical Cardiac Electrophysiology · Orange, CANPI 1013250463
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Edwards Lifesciences at 44.0% of the total. Reporting peaked in 2023 at $30,409 and has fallen 95.2% since, to $1,445 in 2025.
Across 128 payments — averaging $282.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$16K
- Eli Lilly$13K
- Novartis$2K
- Abbott$2K
- Abiomed$814
- Merck$597
- plus $2K from 14 others
Across 16 payments — averaging $20,582 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$235K
- Amgen$50K
- Novartis$44K
What the payments were for
- Consulting fees$15,93844%
- Travel & lodging$14,25739%
- Food & beverage$6,00217%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 1 | $15,938 |
| Eli Lilly | 43 | $13,314 |
| Novartis | 26 | $2,202 |
| Abbott | 12 | $1,598 |
| Abiomed | 12 | $814 |
| Merck | 5 | $597 |
| Novo Nordisk | 8 | $475 |
| Bayer | 5 | $298 |
| Gilead | 2 | $236 |
| Ancora Heart, Inc. | 2 | $203 |
| Amgen | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| AbbVie | 2 | $48 |
| Boehringer Ingelheim | 1 | $46 |
| Terumo Medical Corporation | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Boston Scientific | 2 | $32 |
| Lilly USA, LLC | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$15,938
- LEQVIO$775
- CARDIOMEMS$597
- MK-1242$499
- ENTRESTO$336
- Impella$335
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$274
- HeartMate 3 Left Ventricular Assist Device$269
- HeartMate$148
- HeartMate 3 Left Ventricular Dev$138
- Wegovy$134
- AccuCinch$132
- Ozempic$129
- Repatha$125
- NEXLETOL$124
- Adempas$122
How this compares
$36,197 in reported general payments places this provider in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $158,606 |
| EntrestoSacubitril/Valsartan | 141 | $144,395 |
| JardianceEmpagliflozin | 122 | $117,764 |
| XareltoRivaroxaban | 31 | $29,398 |
| OzempicSemaglutide | 29 | $26,588 |
| FarxigaDapagliflozin Propanediol | 16 | $15,341 |
| MounjaroTirzepatide | 14 | $14,276 |
| Dofetilide | 19 | $4,762 |
| Metoprolol Succinate | 189 | $2,834 |
| Bumetanide | 33 | $2,254 |
| Eplerenone | 47 | $2,244 |
| Rosuvastatin Calcium | 61 | $1,864 |
| Atorvastatin Calcium | 200 | $1,781 |
| Losartan Potassium | 151 | $1,733 |
| Spironolactone | 178 | $1,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $2,202 | $144,395141 claims |
| Boehringer IngelheimJardiance | $46 | $117,764122 claims |
| Johnson & JohnsonXarelto | $17 | $29,39831 claims |
| Novo NordiskOzempic | $475 | $26,58829 claims |
| Lilly USA, LLCMounjaro | $31 | $14,27614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Orange
- Shephal DoshiSanta Monica$2.1M
- Jonathan HsuSan Diego$1.2M
- Leslie SaxonLos Angeles$1.1M
- Rahul BhardwajLoma Linda$935K
- Nicholas Olsonla Jolla$801K
- Jonathan DukesVentura$775K
- Brett GidneySanta Barbara$756K
- John Rogersla Jolla$738K
- Rajesh BankerNewport Beach$538K
- Rahul DoshiLos Angeles$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.